Lynch syndrome, also called Hereditary Non-polyposis Colorectal Cancer (HNPCC) syndrome, is a hereditary cancer syndrome that increases a patient’s risk of developing several different types of cancer, including endometrial and colorectal cancer. Lynch syndrome is linked to mutations in the MLH1, MSH2, EPCAM, MSH6 or PMS2 genes.1
In addition to endometrial and colon cancer, patients with Lynch syndrome are also at higher risk of developing:
Some patients with Lynch syndrome may also develop sebaceous adenomas, noncancerous tumors of the sebaceous glands.
Myriad offers genetic testing to determine whether a patient is a carrier of the MLH1, MSH2, MSH6, PMS2 or EPCAM gene mutations.
If a patient’s personal and family history indicates that he/she may be at increased risk for Lynch syndrome, genetic test results provide the most accurate means of assessing that patient’s cancer risk. Knowing the potential risk can help you and your patient make better, more informed decisions about your patient’s health, before the onset of cancer or before a second cancer has had a chance to develop.
Genetic testing for Lynch syndrome should be considered for hereditary endometrial cancer if:*
You can use the Myriad Hereditary Cancer Quiz as a tool to help you identify patients who may benefit from hereditary cancer testing.
Get Your Custom Hereditary Cancer Quiz
If the Myriad MyRisk™ Hereditary Cancer test confirms the presence of a MLH1, MSH2, MSH6 or PMS2 mutation, the following medical management options may help reduce cancer risk and either delay the onset of endometrial cancer or detect cancer at an earlier, more treatable stage: †
Hereditary cancer gene panel testing results may assist you in developing personalized medical management plans that help to improve patient care by:
*Assessment criteria are based on individual medical society guidelines.
** Lynch-associated cancers include colon, endometrial, gastric, ovarian, ureter/renal, pelvic, biliary tract, small bowel, pancreatic, brain and sebaceous adenomas.
†Any discussion of medical management options is for general informational purposes only and does not constitute a recommendation. While genetic testing and medical society guidelines provide important and useful information, all medical management decisions should be made based on consultation between each patient and his or her healthcare professional.
1. Giardiello FM, et al. Guidelines on Genetic Evaluation and Management of Lynch Syndrome: A Consensus Statement by the US Multi-Society Task Force on Colorectal Cancer. Am J Gastroenterol. 2014 109:1159-79. PMID:25070057.